---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-063806"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T05:26:05.009763+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nektar corrects REZPEG Phase 1b data; atopic dermatitis EASI-75 rate now 41% vs 29% reported by Lilly

## Summary
- Highest REZPEG dose (24 µg/kg) in atopic dermatitis achieved 83% mean EASI improvement (p=0.002 vs placebo).
- EASI-75 response rate corrected from previously reported 29% to 41% (NRI) and 58% as observed.
- Psoriasis data also corrected: PASI-50 rate rose to 32% (NRI) and PASI-75 to 21% (NRI); p-values remained non-significant.
- Errors discovered after Lilly returned rights; independent statistical firm reanalyzed raw data.
- Nektar plans to start Phase 2b study in moderate-to-severe atopic dermatitis in October 2023.

## SEC filing metadata
- accession: 0001213900-23-063806
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390023063806/0001213900-23-063806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390023063806/ea182964-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-063806
- JSON: https://secwatch.observer/filing/0001213900-23-063806.json
- Plain text: https://secwatch.observer/filing/0001213900-23-063806.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.